- Home
- SYRE vs ARE Comparison
SYRE vs ARE Comparison
Compare SYRE & ARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SYRE | ARE |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 7.8B |
| IPO Year | 2015 | 1997 |
Fundamental Metrics
Financial Performance| Metric | SYRE | ARE |
|---|---|---|
| Price | $82.77 | $44.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 18 | 16 |
| Target Price | ★ $119.93 | $51.93 |
| AVG Volume (30 Days) | 1.4M | ★ 1.9M |
| Earning Date | 11-03-2026 | 10-26-2026 |
| Dividend Yield | N/A | ★ 6.53% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.68 |
| Revenue | N/A | ★ $3,026,556,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $26.25 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.01 | $39.41 |
| 52 Week High | $110.18 | $78.54 |
Technical Indicators
Market Signals| Indicator | SYRE | ARE |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 29.31 |
| Support Level | $82.86 | $41.44 |
| Resistance Level | $94.10 | $55.20 |
| Average True Range (ATR) | 4.63 | 1.40 |
| MACD | -0.13 | -0.51 |
| Stochastic Oscillator | 33.91 | 6.10 |
Price Performance
Historical ComparisonAbout SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About ARE Alexandria Real Estate Equities Inc.
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.